Saturday, August 8, 2026
RSS

Pharmaceutical

iRhythm's Strong Q2 Earnings and Vital Connect Acquisition: A Sign of Growth

iRhythm's Q2 earnings beat and acquisition of Vital Connect signal promising growth in wearable health tech.

By Marcus Rivera • August 8, 2026
Pharmaceutical

Eli Lilly's Next-Gen Weight-Loss Drug Filing: A Game Changer for Investors

Eli Lilly's FDA filing for a new weight-loss drug could reshape the market landscape and challenge competitors like Novo Nordisk.

James McAllister • Aug 8
Markets & Money

Celsius Holdings Soars on Rockstar Energy Founder’s Stake Acquisition

Russ Savage's acquisition of a stake in Celsius Holdings sparks speculation and market movement.

Marcus Rivera • Aug 7
Trade with the conviction of the 1%.

Institutional-grade market intelligence delivered before the opening bell.

By subscribing, I agree to receive marketing emails and alerts. View our Privacy Policy. You may unsubscribe at any time.

More Stories
Pharmaceutical

NRx Pharmaceuticals Moves Closer to Launching Preservative-Free Ketamine

NRx Pharmaceuticals' ANDA for preservative-free ketamine passes FDA first-cycle review, signaling significant market pot…

Sarah Chen • Aug 7, 2026
Pharmaceutical

Moderna's mRNA Flu Vaccine Approval: A Milestone with Market Implications

Moderna's recent FDA approval for its mRNA flu vaccine marks a significant step, yet market sentiment remains cautious.

James McAllister • Aug 7, 2026
Critical Minerals

Critical Minerals in Focus: Trump's Meeting with Mining CEOs and Its Market Implications

The Trump administration's focus on critical minerals highlights opportunities for investors in Lomiko Metals and Canadi…

Marcus Rivera • Aug 7, 2026
Markets & Money

US Jobs Report Shock: What the -23K Non-Farm Payrolls Mean for Markets

The unexpected -23,000 non-farm payrolls in July raises questions about market stability and economic outlook.

Sarah Chen • Aug 7, 2026
Pharmaceutical

Harrow's Strategic Acquisition of TYRVAYA: A Game-Changer for Ophthalmic Treatments

Harrow's acquisition of TYRVAYA positions it as a key player in ophthalmic treatments, offering potential revenue growth…

Marcus Rivera • Aug 6, 2026
Pharmaceutical

Tarsus Pharmaceuticals Expands Eye Care Pipeline with Alkeus Acquisition

Tarsus Pharmaceuticals strengthens its eye care portfolio by acquiring Alkeus Pharmaceuticals, focusing on gildeuretinol…

Sarah Chen • Aug 6, 2026
Pharmaceutical

Moderna's Groundbreaking mRNA Flu Vaccine Approval: A New Chapter in Vaccination

Moderna's mFLUSIVA, the first FDA-approved mRNA flu vaccine, is set to reshape the vaccination landscape and boost inves…

James McAllister • Aug 6, 2026
Pharmaceutical

Harrow's Acquisition of TYRVAYA: A Game Changer for Dry Eye Treatment

Harrow Pharmaceuticals acquires TYRVAYA, the first FDA-approved nasal spray for dry eye disease, reshaping the market la…

Marcus Rivera • Aug 6, 2026
Pharmaceutical

Moderna's Historic mRNA Influenza Vaccine Approval: What It Means for Investors

Moderna's mFLUSIVA approval marks a pivotal moment for the company and its investors, showcasing its evolution beyond CO…

James McAllister • Aug 6, 2026